CASI Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally...

Stats
Dzisiejszy wolumen	9 515.00
Średni wolumen	200 148
Kapitalizacja rynkowa	37.46M
EPS	$0 ( 2024-04-01 )
Następna data zysków	( $-0.0500 ) 2024-05-15
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.380
ATR14	$0.0310 (1.11%)

Insider Trading

Date	Person	Action	Amount	type
2022-09-07	Zukiwski Alexander A	Buy	3 000	Employee Stock Option (Right to Buy)
2022-09-06	Huang James	Buy	33 300	Common Stock
2022-08-31	Huang James	Buy	400	Common Stock
2022-08-24	Huang James	Buy	39 527	Common Stock
2022-08-19	Huang James	Buy	40 000	Common Stock

INSIDER POWER
100.00
Last 95 transactions
Buy: 27 815 562 \| Sell: 9 916 643

CASI Pharmaceuticals Inc Korelacja

10 Najbardziej pozytywne korelacje
TTEC	0.951
UONEK	0.948
UONE	0.942
CNXC	0.939
PRTS	0.936
JRJC	0.934
HCDIP	0.933
AMPH	0.929
PHCF	0.929
VORB	0.927

10 Najbardziej negatywne korelacje
RNA	-0.953
PPC	-0.95
VITL	-0.947
GRCL	-0.942
MLAI	-0.941
CRAI	-0.94
MNMD	-0.94
RETA	-0.937
THRN	-0.936
IMPPP	-0.936

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CASI Pharmaceuticals Inc Finanse

Annual	2023
Przychody:	$33.88M
Zysk brutto:	$18.98M (56.03 %)
EPS:	$-2.02

FY	2023
Przychody:	$33.88M
Zysk brutto:	$18.98M (56.03 %)
EPS:	$-2.02

FY	2022
Przychody:	$43.11M
Zysk brutto:	$27.28M (63.28 %)
EPS:	$-2.89

FY	2021
Przychody:	$30.17M
Zysk brutto:	$17.61M (58.38 %)
EPS:	$-0.332

Financial Reports:

No articles found.

CASI Pharmaceuticals Inc

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.